Félicitée Nguefack1, Roger Dongmo1, Carole Leïla Touffic Othman1, Sandra Tatah1, Mina Ntoto Njiki Kinkela1, Paul Olivier Koki Ndombo1. 1. 1 Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, P.O. Box 1364, Cameroon ; 2 Gynaeco-Obstetric and Paediatric Hospital, P.o. Box 4362, Yaoundé, Cameroon ; 3 District Hospital Efoulan PO. Box 1113-Yaoundé, Cameroon ; 4 Mother and Child Centre of the Chantal Biya Foundation, P.O. Box 1444, Yaoundé, Cameroon.
Abstract
BACKGROUND: Rapid progressors are exposed to HIV infection at an early stage of life, and the prognosis is poor without treatment. Reducing the proportion of infants who are rapid progressors, require strengthening strategies to achieve the highest level of performance for the PMTCT program. METHODS: This was a retrospective study carried out on HIV infected infants aged less than 12 months, clinically classified stage 4 (WHO) or having CD4 count <25%. We described maternal and obstetrical characteristics of HIV-infected rapid progressors using univariate and bivariate analysis. Patients' survival was monitored from the inclusion time to the end of the study. We then estimated their probability of survival with or without anti-retroviral (ARV) treatment from birth using the Kaplan-Meier method. RESULTS: The characteristics of the mothers of the 150 rapid progressors infants we included were: low level of education (OR=3.87; P=0.016), CD4 count less than 200/mm(3) (OR=43.3; P=0.000), absence of ARV prophylaxis (OR=6.02; P=0.043), or treatment with HAART (OR=5.74; P=0.000) during pregnancy. In the children, the most important findings were lack of co-trimoxazole prophylaxis (OR=11.61; P=0.000) and antiretroviral prophylaxis (OR=2.70; P=0.0344). The survival rate was 84.3% in infants who were receiving HAART as opposed to 43.3% in those who were not (P<0.05). CONCLUSIONS: HIV infected women who are eligible should start antiretroviral treatment prior to a pregnancy, in order to improve their immunological status. This measure associated to cotrimoxazole prophylaxis and ART could improve their survival.
BACKGROUND: Rapid progressors are exposed to HIV infection at an early stage of life, and the prognosis is poor without treatment. Reducing the proportion of infants who are rapid progressors, require strengthening strategies to achieve the highest level of performance for the PMTCT program. METHODS: This was a retrospective study carried out on HIV infectedinfants aged less than 12 months, clinically classified stage 4 (WHO) or having CD4 count <25%. We described maternal and obstetrical characteristics of HIV-infected rapid progressors using univariate and bivariate analysis. Patients' survival was monitored from the inclusion time to the end of the study. We then estimated their probability of survival with or without anti-retroviral (ARV) treatment from birth using the Kaplan-Meier method. RESULTS: The characteristics of the mothers of the 150 rapid progressors infants we included were: low level of education (OR=3.87; P=0.016), CD4 count less than 200/mm(3) (OR=43.3; P=0.000), absence of ARV prophylaxis (OR=6.02; P=0.043), or treatment with HAART (OR=5.74; P=0.000) during pregnancy. In the children, the most important findings were lack of co-trimoxazole prophylaxis (OR=11.61; P=0.000) and antiretroviral prophylaxis (OR=2.70; P=0.0344). The survival rate was 84.3% in infants who were receiving HAART as opposed to 43.3% in those who were not (P<0.05). CONCLUSIONS:HIV infectedwomen who are eligible should start antiretroviral treatment prior to a pregnancy, in order to improve their immunological status. This measure associated to cotrimoxazole prophylaxis and ART could improve their survival.
Authors: Elaine J Abrams; Jeffrey Wiener; Rosalind Carter; Louise Kuhn; Paul Palumbo; Stephen Nesheim; Francis Lee; Peter Vink; Marc Bulterys Journal: AIDS Date: 2003-04-11 Impact factor: 4.177
Authors: Heena Brahmbhatt; Godfrey Kigozi; Fred Wabwire-Mangen; David Serwadda; Tom Lutalo; Fred Nalugoda; Nelson Sewankambo; Mohamed Kiduggavu; Maria Wawer; Ronald Gray Journal: J Acquir Immune Defic Syndr Date: 2006-04-01 Impact factor: 3.731
Authors: T Evans-Gilbert; R B Pierre; J Steel-Duncan; P Palmer; J P Figueroa; C D C Christie Journal: West Indian Med J Date: 2008-06 Impact factor: 0.171
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: S Blanche; M J Mayaux; C Rouzioux; J P Teglas; G Firtion; F Monpoux; N Ciraru-Vigneron; F Meier; J Tricoire; C Courpotin Journal: N Engl J Med Date: 1994-02-03 Impact factor: 91.245
Authors: Wendy Mphatswe; Natasha Blanckenberg; Gareth Tudor-Williams; Andrew Prendergast; Christina Thobakgale; Nompumelelo Mkhwanazi; Noel McCarthy; Bruce D Walker; Photini Kiepiela; Philip Goulder Journal: AIDS Date: 2007-06-19 Impact factor: 4.177